Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476954 | 0.90 | GAA (0.49) | PTK2HSD17B10TSHRKDM1AGAA | |
| SCHEMBL5480527 | 0.85 | KMT2A (0.49) | PTK2HSD17B10SMN1; SMN2KDM1AGAA | |
| SCHEMBL5474213 | 0.85 | MAOA (0.49) | PTK2HSD17B10TSHRKDM1AGAA | |
| SCHEMBL5476185 | 0.83 | CYP1A2 (0.58) | HSD17B10TSHRTP53CYP1A2CYP3A4 | |
| SCHEMBL5474346 | 0.78 | PDE4B (0.46) | PTK2TP53SMN1; SMN2GAAMAPK1 | |
| SCHEMBL5473971 | 0.74 | ALDH1A1 (0.46) | PTK2SMN1; SMN2GAAJAK2MAPK1 | |
| SCHEMBL5470932 | 0.73 | MAPT (0.43) | PTK2SMN1; SMN2GAAMAPK1LMNA | |
| SCHEMBL5476920 | 0.73 | ALDH1A1 (0.43) | PTK2MAOACYP1A2JAK2MAPK1 | |
| SCHEMBL5467470 | 0.73 | JAK2 (0.47) | PTK2TP53SMN1; SMN2MAOAJAK2 | |
| SCHEMBL5478182 | 0.71 | JAK2 (0.46) | PTK2HSD17B10TP53CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648877-A1 | SUBSTITUTED PYRIDIN-2-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005009980-A1 | SUBSTITUTED PYRIDIN-2-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2023144240-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES AND USES THEREOF | NOVO NORDISK RESEARCH CENTRE OXFORD LIMITED (GB) | 2023-08-03 | — | — | WO | disclosed |
| US-11541122-B2 | Glucose sensitive insulins and uses thereof | ZIYLO LIMITED | 2023-01-03 | — | — | US | disclosed |
| US-20220184184-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2022-06-16 | — | — | US | disclosed |
| US-20220047708-A1 | GLUCOSE SENSITIVE INSULINS AND USES THEREOF | NOVO NORDISK RESEARCH CENTRE OXFORD LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| EP-3946363-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2022-02-09 | — | — | EP | disclosed |
| EP-3852873-A1 | GLUCOSE SENSITIVE INSULINS AND USES THEREOF | Ziylo Ltd (GB) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020201041-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020058322-A1 | GLUCOSE SENSITIVE INSULINS AND USES THEREOF | ZIYLO LTD. (GB) | 2020-03-26 | — | — | WO | disclosed |
| US-20070196344-A1 | Methods for identifying materials that can help regulate the condition of mammalian keratinous tissue | THE PROCTER & GAMBLE COMPANY (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184184-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | IAPP, IRS1, GPR119 | PTK2 1316/4885HSD17B10 923/4885TSHR 2318/4885 |
| US-20070161637-A1 | Substituted pyridin-2-ylamine analogues | PIGS, GPR35, GPR174 | PTK2 1344/4885HSD17B10 3903/4885TSHR 92/4885 |
| US-11541122-B2 | Glucose sensitive insulins and uses thereof | GPR119, IAPP, IRS1 | PTK2 3415/4885HSD17B10 821/4885TSHR 951/4885 |
| US-20220047708-A1 | GLUCOSE SENSITIVE INSULINS AND USES THEREOF | GPR119, IAPP, IRS1 | PTK2 3415/4885HSD17B10 821/4885TSHR 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.